Scaled Production, Dose-Sparing Immunogenicity, and Biodistribution of Short Carbon Nanotubes as mRNA Vaccine Delivery Vehicles
ACS Omega · 03.11.2026 · 11 (43) · 66688-66698
DOI: 10.1021/acsomega.6c06230 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 22.10.2026. Verfasst von Yang Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Luna Labs USA, 706 Forest St., Suite A, Charlottesville, Virginia 22903, United States. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIMH NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Clinical translation of carbon nanotube (CNT)-based biomedical technologies requires a comprehensive understanding of scalable manufacturing, in vivo behavior, and dose efficiency. Here, we investigate NanoVac, a vaccine delivery platform based on functionalized short carbon nanotubes (SCNTs). We achieved scalable production and purification of NanoVac using tangential flow filtration (TFF), providing a reproducible process compatible with future Good Manufacturing Practice (GMP) development. To characterize its in vivo properties, we radiolabeled NanoVac with 89Zr via deferoxamine (DFO) chelation and evaluated it using longitudinal positron emission tomography (PET) imaging. After intramuscular administration in mice, NanoVac showed prolonged retention at the injection site, limited systemic distribution, and minimal accumulation in major organs, including the liver and spleen. NanoVac-associated radioactivity was gradually eliminated through renal and biliary excretion pathways over a 7-day observation period. Compared with other nonlipid nanocarriers, including polymeric nanoparticles and inorganic systems that often face challenges related to biodegradability, toxicity, or large-scale manufacturing, NanoVac combines scalable production with favorable biodistribution and retention characteristics. Immunogenicity studies demonstrated that NanoVac-mediated delivery of HIV-1 trimer-encoding mRNA achieved robust antibody responses at substantially reduced mRNA doses, with low-dose formulations (0.1–1 μg/animal) producing responses comparable to those observed with a 30 μg dose. In addition, NanoVac alone stimulated T-cell responses, supporting its potential role as both a delivery vehicle and an immune-modulating component. These findings establish the manufacturing feasibility, pharmacokinetic profile, and dose-sparing potential of NanoVac, thereby supporting its further development as a scalable vaccine delivery platform for rapid-response applications.
Autor:innen und Institutionen
- Luna Labs USA, 706 Forest St., Suite A, Charlottesville, Virginia 22903, United States.
- Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia 22903, United States.
- University of Virginia Comprehensive Cancer Center, University of Virginia, Charlottesville, Virginia 22903, United States.
- Department of Chemistry, University of Virginia, Charlottesville, Virginia 22903, United States.
- Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia 22903, United States.
- Aaron Diamond AIDS Research Center, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York 10032, United States.
ORCID-Profile: Yang Xu
Förderung
- NIAID NIH HHS
- NIMH NIH HHS
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- NIH Office of the Director
- National Institute of Allergy and Infectious Diseases
- National Institute of Mental Health
Zitieren
APA
Xu, Y., Vest, O., Brooks, B., McNeal, J., Jansen, M. A., He, J., Tsuji, M., & Tison, C. (2026). Scaled Production, Dose-Sparing Immunogenicity, and Biodistribution of Short Carbon Nanotubes as mRNA Vaccine Delivery Vehicles. ACS Omega, 11(43), 66688-66698. https://doi.org/10.1021/acsomega.6c06230
Vancouver
Xu Y, Vest O, Brooks B, McNeal J, Jansen MA, He J, et al. Scaled Production, Dose-Sparing Immunogenicity, and Biodistribution of Short Carbon Nanotubes as mRNA Vaccine Delivery Vehicles. ACS Omega. 2026;11(43):66688-66698. doi:10.1021/acsomega.6c06230
BibTeX
@article{Xu2026,
author = {Xu, Yang and Vest, Olivia and Brooks, Brad and McNeal, Jackson and Jansen, Maurits A and He, Jiang and Tsuji, Moriya and Tison, Christopher},
title = {Scaled Production, Dose-Sparing Immunogenicity, and Biodistribution of Short Carbon Nanotubes as mRNA Vaccine Delivery Vehicles},
journal = {ACS Omega},
year = {2026},
volume = {11},
number = {43},
pages = {66688--66698},
doi = {10.1021/acsomega.6c06230}
}
EUVIMED